Eurestobart Biosimilar - Research Grade

Human

ENTPD1

>1mg/ml

IgG1 - kappa

CHO Cells

IPH5201 Biosimilar - Research Grade (ICH5218), Perenostobart Biosimilar - Research Grade (ICH5265)

https://www.imgt.org/mAb-DB/

ICH3002

P49961

Blue ice

This product (ICH5537) is an unconjugated, non-therapeutic recombinant analog of eurestobart, an anti-CD39 (ENTPD1) IgG1-kappa antibody, supplied strictly for research use only. It is built around the same human target, ENTPD1 (UniProt P49961), and is intended to reproduce the binding behavior of the originator molecule in laboratory settings, not to serve as the clinical drug. It is not for human or veterinary use. Because CD39 sits at the apex of the adenosinergic pathway, a well-characterized anti-CD39 analog is a useful tool for probing purinergic signaling, ATP hydrolysis, and immunosuppressive adenosine generation in vitro. Typical research applications include target-binding and epitope characterization, enzyme-neutralization assays, use as a positive control or benchmark reagent against internal candidates, ADCC/ADC-development workflows, and preclinical model work. The material is produced as a recombinant IgG1-kappa and is available at low-endotoxin research grade (<1 EU/mg), with ultra-low endotoxin (<0.5 EU/mg) and bulk milligram-to-gram quantities for assay standardization and scale-up. Lot-appropriate formulation supports flexible downstream use across binding, functional, and control experiments. ENTPD1, better known as CD39, is a cell-surface ectonucleotidase (ectonucleoside triphosphate diphosphohydrolase-1) that catalyzes hydrolysis of extracellular ATP and ADP to AMP. Acting in tandem with CD73 (which converts AMP to adenosine), CD39 governs the switch from a pro-inflammatory, ATP-rich microenvironment to an immunosuppressive, adenosine-rich one. It is the dominant ectonucleotidase on regulatory T cells and vascular endothelium and is also expressed on subsets of myeloid cells, B cells, and many tumors. By depleting immunostimulatory ATP and feeding adenosine production, CD39 dampens effector T-cell and NK-cell responses. This positions CD39/ENTPD1 as a central node in purinergic immunoregulation and a widely studied target in oncology, inflammation, and fibrosis research.

ATP diphosphohydrolase, ATP-DPH, ATPDase, Ecto-ATP diphosphohydrolase 1, Ecto-ATPDase 1, Ecto-ATPase 1, Ecto-apyrase, Lymphoid cell activation antigen, Nucleoside triphosphate diphosphohydrolase 1, NTPDase1, Ectonucleoside triphosphate diphosphohydrolase

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks